Genomics is a comprehensive study of the whole genome, genetic products, and their interactions. Human genome project has identified around 25,000-30,000 genes, and prevailing presence in tumor pathogenesis, high number of mutations, epigenetic changes, and other gene disorders have been identified. Microarrays technology is used for the analysis of these changes. Postgenome age has begun, and the initial results ensure the improvement of molecular tumor diagnostics and the making of a new taxonomic tumor classification, as well as the improvement, optimization and individualization of anti-tumor therapy. First genomic classifications have been made of leukemias, non-Hodgkin lymphoma, and many solid tumors. For example, 4 molecular types of breast carcinoma, three types of diffuse B cell lymphoma, two types of chromophobic renal carcinoma have been identified. Also, gene structures for favorable and unfavorable outcome in leukemia, breast cancer, prostate, bronchi, and other tumors have been identified. It is absolutely possible to diagnose the primary outcome of tumors with which standard tumor position may not be proved using standard diagnostic tools. Pharmacogenomic profiles have ensured better definition of interindividual differences during therapy using antineoplastic drugs and the decrease of their toxicity, as well as individual treatment approach and patient selection with which favorable clinical outcome is expected. Pharmacogenomics has impacted the accelerated development of target drugs, which have showed to be useful in practice. New genomic markers mtDNA, meDNA, and miRNA have been identified, which, with great certainty, help the detection and diagnostics of carcinoma. In the future, functional genomics in clinical oncology provides to gain knowledge about tumor pathogenesis; it will improve diagnostics and prognosis, and open up new therapeutic options. Genomika je sveobuhvatna studija celokupnog genoma, genskih produkata i njihovih interakcija. Projekat ljudskog genoma identifikovao je oko 30.000 gena i preovladstrock;ujuće prisustvo intergenskih sekvenci. U onkogenima, supresornim genima tumora i dr. genima koji imaju ulogu u patogenezi tumora, identifikovan je veliki broj mutacija, epigenetskih promena i dr. genskih poremećaja. Za analizu ovih promena upotrebljava se mikroarej tehnologija. Postgenomska era je počela, i prvi rezultati omogućavaju da se poboljša molekularna dijagnostika tumora i izvrši nova taksonomska klasifikacija tumora, kao i da se poboljša, optimalizuje i individualizuje antitumorska terapija. Izvršene su prve genomske klasifikacije leukemija, non-Hodgkin limfoma i mnogih solidnih tumora. Na primer, identifikovana su 4 molekularna tipa karcinoma dojke, tri tipa difuznog B ćelijskog limfoma, dva tipa papilarnog karcinoma bubrega. Takodstrock;e, identifikovane su genske signature za povoljan i nepovoljan ishod u lečenju leukemije, karcinoma dojke, prostate, bronha i dr. tumora. Apsolutno je moguće dijagnostikovati primarno ishodište u tumora kod kojih se standardnim dijagnostičkim sredstvima ne može dokazati primarno ležište tumora. Farmakogenomski profili omogućili su bolje definisanje interindividualnih razlika u toku terapije antineoplastičnim lekovima i smanjenje njihove toksičnosti, kao i individualni pristup u lečenju i selekciju pacijenata u kojih se očekuje povoljan klinički ishod. Farmakogenomika je uticala na ubrzani razvoj ciljanih lekova, koji su se u praksi pokazali svrsishodnim. Identifikovani su novi genomski markeri mtDNA, meDNA i miRNA, koji sa velikom sigurnošću pomažu u detekciji i dijagnostici karcinoma. U budućnosti, funkcionalna genomika u kliničkoj onkologiji omogućće upoznavanje patogeneze tumora, poboljšaće molekularnu dijagnostiku, prognozu, i otvoriti nove terapijske opcije.